CJ HealthCare applies new drug approval of acid reflex treatment
The CJ HealthCare’s first new medicine, an acid reflux treatment, has taken a approval process in Korea its launch.
CJ HealthCare(CEO Seok-Hee Kang) announced on the 4th that it applied product approval of ‘tegoprazan(Code name: CJ-12420),’ a new acid reflux treatment, to the Ministry of Food an...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
